Company / Shareholders' Equity
X4 Pharmaceuticals, Inc Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$22.1M
FY2025
5-year range
-$77.1M / $129.2M
FY2021-FY2025
Trend
-70.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 6 years, ranging from -$77M in FY2020 to $129M in FY2021.
Based on SEC 10-K filings.
$22M in FY2025 with a 3-year CAGR of -32.7%.
Declined from $73M to $22M over the past 3 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -32.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -32.7%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 70.1% year-over-year.
- Peak shareholders' equity was recorded in FY2021.
- Lowest shareholders' equity in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.1M | -70.1% |
| FY2024 | $74.1M | +1.7% |
| FY2022 | $72.8M | -43.7% |
| FY2021 | $129.2M | +267.6% |
| FY2020 | -$77.1M | -36.3% |
| FY2018 | -$56.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026